Adjuvant and neoadjuvant therapies in high risk localized prostate cancer (Journal article)

Giannakopoulos, X./ Stagikas, D./ Charalabopoulos, A./ Sofikitis, N./ Charalabopoulos, K.

In this review article adjuvant and neoadjuvant therapies in patients at high risk for localized prostate cancer are presented in some detail. Adjuvant hormone therapy by antiandrogens as well as antineoplastic chemotherapeutic agents such as estramustine and taxanes are referred. Neoadjuvant therapies in addition to systemic therapy before or after local treatment for prostate cancer may improve the outcome of high risk patients otherwise destined to treatment fail. Data regarding some substances used in neoadjuvant therapies such as androgen deprivation therapy and use of rapamycin with its analogs, as well as some novel therapeutic approach strategies are also discussed.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Androgen Antagonists/therapeutic use,Chemotherapy, Adjuvant,Humans,Male,Neoadjuvant Therapy,Prostatic Neoplasms/drug therapy/pathology/surgery/*therapy,Radiotherapy, Adjuvant
ISSN: 0392-9078
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.